CD19

CD19 是一种在人类 B 细胞和某些类型的肿瘤中高度表达的 95 kD 跨膜糖蛋白,属于免疫球蛋白超家族。CD19 通过调节 B 细胞受体 (BCR) 依赖性和非依赖性信号通路,参与调控 B 细胞信号的阈值,从而对免疫反应的启动和耐受性维持起到至关重要的作用。CD19 通常与 CD21 和 CD81 等分子一起形成多分子复合物,在成熟的 B 细胞表面发挥其主导的信号功能。
CD19 可通过与 BCR 的协作,促进 Src 家族蛋白酪氨酸激酶的激活,增强 B 细胞增殖和扩展。CD19 还能够独立于 BCR 通过与补体受体 CD21 结合,增强 B 细胞的激活。CD19 缺乏的小鼠和人类显示出较弱的 T 细胞依赖性免疫反应和低水平的免疫球蛋白,导致免疫功能缺陷。CD19 的高表达与 B 细胞淋巴瘤、急性淋巴细胞白血病 (ALL) 等恶性肿瘤密切相关。CD19 单克隆抗体被用于 B 细胞恶性肿瘤的研究[1]。

CD19 is a 95 kD transmembrane glycoprotein that is highly expressed in human B cells and certain types of tumors, belonging to the immunoglobulin superfamily. CD19 plays a crucial role in regulating the threshold of B cell signaling by modulating both B cell receptor (BCR)-dependent and independent signaling pathways, thereby playing an essential role in the initiation of immune responses and the maintenance of tolerance. CD19 typically forms a multimolecular complex with molecules like CD21 and CD81 on the surface of mature B cells, where it exerts its dominant signaling function.
CD19 works in cooperation with the BCR to promote the activation of Src family protein tyrosine kinases, enhancing B cell proliferation and expansion. It can also independently enhance B cell activation by binding to the complement receptor CD21. Mice and humans lacking CD19 show weakened T cell-dependent immune responses and low levels of immunoglobulins, leading to immune dysfunction. High expression of CD19 is closely associated with B cell lymphoma, acute lymphoblastic leukemia (ALL), and other malignancies. CD19 monoclonal antibodies are used in the study of B cell malignancies[1].

共 1种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
RG-6333
RO7443904

RG-6333 是一种靶向 CD19 和 CD28 的双特异性激动剂,能特异性识别并结合 B 细胞恶性肿瘤表面的 CD19 抗原以定位肿瘤细胞,并通过与 CD28 结合激活 T 细胞、克服激活障碍、增强抗肿瘤免疫力,可用于复发/难治性非霍奇金淋巴瘤的研究,推荐同型对照为 human IgG1 kappa,同型对照 (MS-E04981)。

Agonist
98.05%
RG-6333

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础